About Us

Overview

Theriva™ is a clinical-stage immuno-oncology company developing oncolytic viruses intended to overcome the protective barrier surrounding solid tumors and selectively kill tumor cells. Our developmental therapies stem from the laboratory of Dr. Ramon Alemany, recognized world-wide as a key opinion leader in adenovirus technologies, and are designed to enable systemic delivery and have the potential to enhance current standard-of-care treatments.

Our team is comprised of determined and experienced leaders who are committed to offering patients with difficult-to-treat cancers the chance of a longer life. We are fueled by our deep desire to change outcomes by working to improve the current standard of care and transform the cancer therapy landscape.

LEADERSHIP

Steven Shallcross
Steven Shallcross
Chief Executive Officer,
Chief Financial Officer,
Director
Manel Cascallo
Manel Cascallo, PhD
General Director,
EU Subsidiary
Vince Wacher
Vince Wacher, PhD
Head of Corporate &
Product Development

SCIENTIFIC ADVISORY BOARD

Board of Directors

Jeffrey J. Kraws
Chairman
Jeffrey Wolf, JD
Director
John Monahan, Ph.D.
Director
Steven Shallcross
Chief Executive Officer,
Chief Financial Officer,
Director
lines
lines

Careers

We’re seeking talented and driven scientists, marketers, analysts, and engineers who share in our mission.

See our job openings